Can a Once-a-Month shot tame MS relapses?

NCT ID NCT04121221

Completed Disease control Sponsor: Mapi Pharma Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This phase III trial is testing whether a long-acting form of glatiramer acetate, called GA Depot, given as a monthly injection, can reduce the number of relapses in people with relapsing-remitting multiple sclerosis (MS). The study involves about 1,000 adults aged 18 to 55 with MS, who will receive either GA Depot or a placebo injection every four weeks for a year. Researchers will track relapse rates and brain MRI changes to see if this less frequent dosing is effective and safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GA Depot, a long-acting form of glatiramer acetate given as an intramuscular injection once every four weeks
What this could lead to: If successful, this could offer a more convenient treatment option for relapsing-remitting MS, potentially reducing relapse rates with fewer injections.
What could go wrong: The trial is still in phase III, and results may not confirm benefit. Possible risks include injection-site reactions and other side effects common to glatiramer acetate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS, RELAPSING-REMITTING

Contacts and locations

Locations

Mapi Pharma Research site 01

Northbrook, Illinois, 60062, United States
Mapi Pharma Research site 01

Vitebsk, Belarus
Mapi Pharma Research site 01

Sarajevo, Bosnia and Herzegovina
Mapi Pharma Research site 01

Pleven, Bulgaria
Mapi Pharma Research site 01

Tallinn, Estonia
Mapi Pharma Research site 01

Tbilisi, Georgia
Mapi Pharma Research site 01

Safed, Israel
Mapi Pharma Research site 01

Chisinau, Moldova
Mapi Pharma Research site 01

Kazan', Russia
Mapi Pharma Research site 01

Zaporizhzhya, Ukraine
Mapi Pharma Research site 02

Detroit, Michigan, 48201, United States
Mapi Pharma Research site 02

Homyel, Belarus
Mapi Pharma Research site 02

Pleven, Bulgaria
Mapi Pharma Research site 02

Tbilisi, Georgia
Mapi Pharma Research site 02

Tel Aviv, Israel
Mapi Pharma Research site 02

Chisinau, Moldova
Mapi Pharma Research site 02

Nizhny Novgorod, Russia
Mapi Pharma Research site 02

Zaporizhzhya, Ukraine
Mapi Pharma Research site 03

Tuzla, Bosnia and Herzegovina
Mapi Pharma Research site 03

Pleven, Bulgaria
Mapi Pharma Research site 03

Tbilisi, Georgia
Mapi Pharma Research site 03

Moscow, Russia
Mapi Pharma Research site 03

Dnipro, Ukraine
Mapi Pharma Research site 04

Round Rock, Texas, 78681, United States
Mapi Pharma Research site 04

Minsk, Belarus
Mapi Pharma Research site 04

Banja Luka, Bosnia and Herzegovina
Mapi Pharma Research site 04

Sofia, Bulgaria
Mapi Pharma Research site 04

Tbilisi, Georgia
Mapi Pharma Research site 04

Ufa, Russia
Mapi Pharma Research site 04

Dnipro, Ukraine
Mapi Pharma Research site 05

Minsk, Belarus
Mapi Pharma Research site 05

Sofia, Bulgaria
Mapi Pharma Research site 05

Tbilisi, Georgia
Mapi Pharma Research site 05

Samara, Russia
Mapi Pharma Research site 05

Odesa, Ukraine
Mapi Pharma Research site 06

Minsk, Belarus
Mapi Pharma Research site 06

Bihać, Bosnia and Herzegovina
Mapi Pharma Research site 06

Sofia, Bulgaria
Mapi Pharma Research site 06

Tbilisi, Georgia
Mapi Pharma Research site 06

Perm, Russia
Mapi Pharma Research site 06

Chernihiv, Ukraine
Mapi Pharma Research site 07

Vitebsk, Belarus
Mapi Pharma Research site 07

Pleven, Bulgaria
Mapi Pharma Research site 07

Tbilisi, Georgia
Mapi Pharma Research site 07

Nizhny Novgorod, Russia
Mapi Pharma Research site 07

Zaporizhzhya, Ukraine
Mapi Pharma Research site 08

Birmingham, Alabama, 35209, United States
Mapi Pharma Research site 08

Sofia, Bulgaria
Mapi Pharma Research site 08

Tbilisi, Georgia
Mapi Pharma Research site 08

Rostov-on-Don, Russia
Mapi Pharma Research site 08

Kherson, Ukraine
Mapi Pharma Research site 09

Miami, Florida, 33136, United States
Mapi Pharma Research site 09

Veliko Tarnovo, Bulgaria
Mapi Pharma Research site 09

Tbilisi, Georgia
Mapi Pharma Research site 09

Saint Petersburg, Russia
Mapi Pharma Research site 09

Kharkiv, Ukraine
Mapi Pharma Research site 10

Pazardzhik, Bulgaria
Mapi Pharma Research site 10

Nizhny Novgorod, Russia
Mapi Pharma Research site 10

Kharkiv, Ukraine
Mapi Pharma Research site 11

Cullman, Alabama, 35058, United States
Mapi Pharma Research site 11

Sofia, Bulgaria
Mapi Pharma Research site 11

Novosibirsk, Russia
Mapi Pharma Research site 11

Chernivtsi, Ukraine
Mapi Pharma Research site 12

Washington D.C., District of Columbia, 20007, United States
Mapi Pharma Research site 12

Plovdiv, Bulgaria
Mapi Pharma Research site 12

Lviv, Ukraine
Mapi Pharma Research site 13

Westerville, Ohio, 43081, United States
Mapi Pharma Research site 13

Sofia, Bulgaria
Mapi Pharma Research site 13

Moscow, Russia
Mapi Pharma Research site 13

Lviv, Ukraine
Mapi Pharma Research site 14

Denver, Colorado, 80209, United States
Mapi Pharma Research site 14

Haskovo, Bulgaria
Mapi Pharma Research site 14

Moscow, Russia
Mapi Pharma Research site 14

Poltava, Ukraine
Mapi Pharma Research site 15

Pasadena, California, 91105, United States
Mapi Pharma Research site 15

Sofia, Bulgaria
Mapi Pharma Research site 15

Smolensk, Russia
Mapi Pharma Research site 16

Sofia, Bulgaria
Mapi Pharma Research site 16

Tyumen, Russia
Mapi Pharma Research site 16

Vinnitsa, Ukraine
Mapi Pharma Research site 17

Homestead, Florida, 33032, United States
Mapi Pharma Research site 17

Vratsa, Bulgaria
Mapi Pharma Research site 17

Ulyanovsk, Russia
Mapi Pharma Research site 17

Lutsk, Ukraine
Mapi Pharma Research site 18

Rousse, Bulgaria
Mapi Pharma Research site 18

Saint Petersburg, Russia
Mapi Pharma Research site 18

Ivano-Frankivsk, Ukraine
Mapi Pharma Research site 19

Sofia, Bulgaria
Mapi Pharma Research site 19

Kemerovo, Russia
Mapi Pharma Research site 20

Saint Petersburg, Russia
Mapi Pharma Research site 20

Zaporizhzhya, Ukraine
Mapi Pharma Research site 21

Moscow, Russia
Mapi Pharma Research site 21

Kyiv, Ukraine
Mapi Pharma Research site 22

Pyatigorsk, Russia
Mapi Pharma Research site 23

Chelyabinsk, Russia
Mapi Pharma Research site 23

Lviv, Ukraine
Mapi Pharma Research site 24

Krasnodar, Russia
Mapi Pharma Research site 24

Dnipro, Ukraine
Mapi Pharma Research site 25

Moscow, Russia
Mapi Pharma Research site 25

Kyiv, Ukraine
Mapi Pharma Research site 26

Saransk, Russia
Mapi Pharma Research site 26

Ivano-Frankivsk, Ukraine
Mapi Pharma Research site 27

Bryansk, Russia
Mapi Pharma Research site 27

Ivano-Frankivsk, Ukraine
Mapi Pharma Research site 28

Moscow, Russia
Mapi Pharma Research site 28

Kyiv, Ukraine
Mapi Pharma Research site 29

Barnaul, Russia
Mapi Pharma Research site 29

Kyiv, Ukraine
Mapi Pharma Research site 31

Uzhhorod, Ukraine
Mapi Pharma Research site 32

Cherkasy, Ukraine
Mapi Pharma Research site 33

Zhytomyr, Ukraine
Mapi Pharma Research site 34

Ternopil, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.